NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30

Neuphoria Therapeutics Inc.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026

$3.31+0.01 (+0.30%)

Close on Oct 19, 2026

Community

Notes and questions about Neuphoria Therapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Neuphoria Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2160 reverse split on Feb 14, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NEUP.

Revenue growth-92.5% · median -14.0%

Operating margin-1401.1% · median -986.8%

Net margin-1145.7% · median -702.1%

Advertisement
300 × 250